Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CD36 Antibodies

CD36, also known as fatty acid translocase (FAT), is a membrane-bound glycoprotein encoded by the CD36 gene on chromosome 7q11.2. It consists of approximately 472 amino acids, resulting in a molecular weight of approximately 88 kDa. Post-translational modifications of CD36 include phosphorylation, glycosylation, and palmitoylation. CD36 is a membrane protein that facilitates the uptake of long-chain fatty acids and oxidized low-density lipoproteins (LDL) into cells, playing a crucial role in lipid metabolism and storage. CD36 also serves as a scavenger receptor involved in clearing apoptotic cells, bacteria, and modified lipoproteins, contributing to immune responses and inflammation. 

CD36 is expressed on various cell types, including adipocytes, muscle cells, macrophages, and endothelial cells, and is a platelet and microvessel marker. Protein expression is regulated by various factors, including dietary fat intake, insulin levels, and inflammatory cytokines, which influence its expression levels in different tissues and physiological conditions. Mutations in the CD36 gene or alterations in its expression have been associated with metabolic disorders, such as dyslipidemia, insulin resistance, and atherosclerosis. Additionally, CD36 has been implicated in the pathogenesis of cardiovascular diseases, including coronary artery disease and ischemic stroke, as well as in inflammatory conditions, such as diabetes and obesity.

In the context of disease, particularly cancer, CD36 expression has garnered significant attention for its potential diagnostic and prognostic value. Across multiple cancer types, such as breast cancer, prostate cancer, colorectal cancer, and glioblastoma, CD36 expression patterns have been examined for their utility in tumor classification and staging. Studies have indicated correlations between CD36 expression levels, tumor aggressiveness, metastatic potential, and patient outcomes. Notably, high CD36 expression has been associated with poor prognosis in some cancers, such as breast cancer, where it is linked to increased metastasis and reduced survival. However, CD36 expression has been associated with favorable outcomes in other contexts, as seen in colorectal cancer. Functionally, CD36 has been implicated in various aspects of cancer progression, including tumor cell survival, proliferation, invasion, angiogenesis, and modulation of the tumor microenvironment. Its involvement in fatty acid uptake and metabolism further underscores its potential role in tumor energetics and therapy resistance. While CD36 holds promise as a diagnostic and prognostic marker in cancer, further research is necessary to elucidate its mechanisms of action and potential therapeutic implications.

NeoBiotechnologies offers a variety of antibodies against CD36 that have been validated for flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting. Additionally, we hold exclusive rights to CD36 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=cd36].


Platelet glycoprotein 4, Fatty acid translocase, Glycoprotein IIIb, Leukocyte differentiation antigen CD36, PAS IV, PAS-4, Platelet collagen receptor, Platelet glycoprotein IV, Thrombospondin receptor, Adipocyte membrane protein; CHDS7; Collagen receptor, platelet; fatty acid translocase (FAT); Fatty acid transport protein; glycoprotein iiib (GP IIIb); PAS IV; PAS-4; pas4 protein; platelet collagen receptor; Platelet glycoprotein 4; scarb3; Scavenger receptor class B member 3; thrombospondin receptor

Research Areas

Autophagy, Cardiovascular, Developmental Biology, Immunology, Cytokine Signaling, Endothelial Cell Marker, Hematopoietic Stem Cells, Infectious Disease

Showing all 8 results


Showing all 8 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.